The first study, conducted at Ruhr University Eye Hospital in Germany, evaluated the safety and efficacy of epithelium-off PiXL using Avedro’s KXL II syst on 39 eyes (phakic and pseudophakic) divided into two groups. Results at 12 months donstrated significant improvent with mean uncorrected VA of 20/20 and no loss of best corrected visual acuity (BCVA).{{quote-A:R-W:450-I:2-Q: This technology has huge potential as an addition to our armamentarium for refractive corrections, -WHO:Dr Lim Wee Kiak, co-founder and group Chief Executive Officer of Eagle Eye Centre}}The second study, performed at the Eagle Eye Centre in Singapore, analysed the safety and efficacy of trans-epithelial PiXL in correcting low myopia. Eight patients (14 myopic eyes) who underwent the procedure were followed for nine months post-operatively. Efficacy findings included a mean myopia reduction of 0.75 D; safety evaluations found no significant loss in endothelial cell count or BCVA, and no significant corneal haze post-procedure; and patients reported a high level of patient satisfaction.“This technology has huge potential as an addition to our armamentarium for refractive corrections,” Dr Lim Wee Kiak of the Eagle Eye Centre stated.
Alcon, RxSight collaborating on adjustable IOL for presbyopia
Alcon, a global leader in eyecare, and RxSight, an ophthalmic medical device company providing high-quality customised vision to patients following...
